E-DRUG: NYT on Brazil's Right to Save Lives (2)
--------------------------------------------------
Colleagues,
If Brazil is exercising its right to issue compulsory licenses on some
ARVs, and that this action is within the WTO Rules, why should that
action be phrased / designed as a threat to patent holders who have
refused to reduce their prices? Surely, Brazil simply needs to
exercise that right, seek to agree a fee to be paid to the patent
holders, as indicated, and carry on with its decision (unless they
cannot proceed without consent from patent holders). In my view, there
is no need for controversy in this action; the ball is in the patent
holder's court: either to agree to reducing product price (one
option), or to support compulsory licensing (second option) which is
the very facility designed to protect patent holder interests.
Regards,
Bonnie
Bonface Fundafunda PhD, MBA, B.Pharm(Hon)
Birkevej 32, Tranegilde Strand, 2635 Ishoj,
Denmark
"BONFACE FUNDAFUNDA" <bcfunda@hotmail.com>